Neoadjuvant paclitaxel polymersomes with carboplatin and adebrelimab for resectable mucosal melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Patients with resectable mucosal melanoma will receive three 3-week cycles of paclitaxel polymersomes, carboplatin, and adebrelimab prior to curative surgery. After completing three cycles, participants undergo surgery and pathologists evaluate the resected tissue for pathological response. Immunohistochemical assays will measure immune activation within the tumor microenvironment. The primary endpoint is pathological response rate and entry requires ECOG 0–1, measurable disease, no prior checkpoint inhibitor or taxane therapy, and adequate organ function.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years old.
2. Histopathologically confirmed resectable mucosal melanoma.
3. Subjects must provide 5 formalin-fixed paraffin-embedded (FFPE) tissue sections collected before treatment, or be willing to undergo needle biopsy for pathological tissue acquisition to facilitate pathological assessment.
4. ECOG (Performance Status, PS) score of 0-1.
5. No prior treatment with immune checkpoint inhibitors such as anti-CTLA-4, anti-PD-1, or anti-PD-L1 monoclonal antibodies.
6. No prior treatment with taxane-based drugs.
7. Presence of measurable lesions (per RECIST 1.1 criteria).
8. No history of immunosuppressant use within 6 months prior to enrollment.
9. Hematological and biochemical test results meeting the following criteria:

   i. Neutrophil count ≥ 1,500 × 10⁹/L; ii. Platelet count ≥ 100 × 10⁹/L; iii. Hemoglobin \> 9.0 g/dL; iv. Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance (CrCl) ≥ 40 mL/min; v. Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤ 3 × ULN; vi. Total bilirubin ≤ 1.5 × ULN.
10. Women of childbearing potential must have a negative serum or urine pregnancy test and agree to use an appropriate contraceptive method (barrier contraception or oral contraceptives).

Exclusion Criteria:

1. Presence of distant metastatic lesions.
2. Active autoimmune disease. Note: Patients with vitiligo, type 1 diabetes mellitus, or Hashimoto's thyroiditis with hypothyroidism who only require hormone replacement therapy may be enrolled if there is no evidence of significant disease recurrence.
3. Need for systemic corticosteroid therapy (\> 10 mg prednisolone \[or equivalent\]/daily) or other immunosuppressant use within 14 days after enrollment. Note: Inhaled or topical corticosteroids, or adrenal hormone replacement therapy (\> 10 mg prednisolone \[or equivalent\]/daily) are acceptable for patients without obvious autoimmune diseases.
4. Concurrent diagnosis of other malignant tumors requiring anti-tumor treatment. Note: Patients may be considered for enrollment if the other malignant tumor has achieved complete remission for 2 years or more and no additional anti-tumor treatment is required during the study period.
5. Patients who are medically, psychologically, or physically unable to complete the study or understand the information provided in the patient brochure, as assessed by the investigator.
6. Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or other drugs targeting T-cell costimulatory or immune regulatory pathways.
7. Prior chemotherapy with taxane-based drugs.
8. Positive HIV test result or confirmed diagnosis of acquired immunodeficiency syndrome (AIDS).
9. Known hypersensitivity to the study drugs.
10. Pregnant or lactating women.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: xizhiwen wen
• Email: wenxz@sysucc.org.cn
• Phone: +8602087343381

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anatomic vs nonanatomic liver resection after conversion therapy for liver cancer

  This study tests whether removing more precisely targeted liver tissue (anatomic resection) works better than removing tissue more broadly (nonanatomic) for patients whose unresectable liver cancer became eligible for surgery after PD-1/PD-L1–based therapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07927452

• AI-assisted imaging for diagnosing and managing focal liver lesions

  Researchers are testing whether AI-powered imaging can help doctors better diagnose focal liver lesions in adults undergoing CT scans.

  Recruiting at 2 sites Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07926672

• HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy

  This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07874308

• Anlotinib Plus PD-1 Inhibitor vs PD-1 Inhibitor Alone After Chemoimmunotherapy in Advanced ESCC

  This trial tests whether adding anlotinib to PD-1 inhibitor maintenance after initial chemoimmunotherapy helps people with advanced esophageal squamous cell carcinoma live longer without the cancer growing.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07863141

• Cryoablation with liver-directed immunotherapy and targeted therapy for melanoma liver metastases

  This trial tests a combination therapy including cryoablation, hepatic artery delivery of QL1706, intravenous dacarbazine, and oral lenvatinib to treat liver metastases from malignant melanoma in adults.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07847359

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.